UNITED THERAPEUTICS Corp

UTHR 10-Q · Q1 2026
API behind this page

UTHR Q1 2026 request

Playground key active
Request URL /api/financials?ticker=UTHR&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 781.5 794.4 -1.6%
Show Product Lines breakouts
Adcirca 2.9 6 -51.7%
Adcirca · US 2.9 6 -51.7%
Nebulized Tyvaso 127.2 163.8 -22.3%
Nebulized Tyvaso · Non Us 14.6 25.2 -42.1%
Nebulized Tyvaso · US 112.6 138.6 -18.8%
Orenitram 135.6 120.7 +12.3%
Orenitram · US 135.6 120.7 +12.3%
Product And Service Other 5.3 5 +6.0%
Product And Service Other · Non Us 0.3 0.3 0.0%
Product And Service Other · US 5 4.7 +6.4%
Remodulin 126.6 138.2 -8.4%
Remodulin · Non Us 17.8 18 -1.1%
Remodulin · US 108.8 120.2 -9.5%
Total Tyvaso 457.5 466.3 -1.9%
Total Tyvaso · Non Us 14.6 25.2 -42.1%
Total Tyvaso · US 442.9 441.1 +0.4%
Tyvaso DPI 330.3 302.5 +9.2%
Tyvaso DPI · US 330.3 302.5 +9.2%
Unituxin 53.6 58.2 -7.9%
Unituxin · Non Us 4.6 1.3 +253.8%
Unituxin · US 49 56.9 -13.9%
Show Geography breakouts
Non Us 37.3 44.8 -16.7%
US 744.2 749.6 -0.7%
Cost of Revenue 133.4 92.5 +44.2%
Show Product Lines breakouts
Adcirca 1 2.6 -61.5%
Nebulized Tyvaso 8.6 8.5 +1.2%
Orenitram 7.4 8.3 -10.8%
Product And Service Other 12.1 6 +101.7%
Remodulin 16.1 13.8 +16.7%
Tyvaso DPI 83.2 48.1 +73.0%
Unituxin 5 5.2 -3.8%
Research & Development 138.2 149 -7.2%
Selling, General & Administrative 184.1 170.1 +8.2%
Total Costs & Expenses 455.7 411.6 +10.7%
Operating Income 325.8 382.8 -14.9%
Interest Income 41.8 51.1 -18.2%
Interest Expense -3 -6.1 +50.8%
Other Non-Operating Income (Expense) -46.3 -4.3 -976.7%
Non-Operating Income (Expense) -7.5 40.7 -118.4%
Income Before Taxes 318.3 423.5 -24.8%
Income Tax Expense (Benefit) -43.4 -101.3 +57.2%
Net Income 274.9 322.2 -14.7%
Show Equity Components breakouts
Retained Earnings 274.9 322.2 -14.7%
EPS (Basic) 6.32 7.18 -12.0%
EPS (Diluted) 5.82 6.63 -12.2%
Wtd Avg Shares (Basic) 43.5 44.9 -3.1%
Wtd Avg Shares (Diluted) 47.2 48.6 -2.9%
Gross Profit 648.1 701.9 -7.7%
Show Product Lines breakouts
Adcirca 1.9 3.4 -44.1%
Nebulized Tyvaso 118.6 155.3 -23.6%
Orenitram 128.2 112.4 +14.1%
Product And Service Other -6.8 -1 -580.0%
Remodulin 110.5 124.4 -11.2%
Tyvaso DPI 247.1 254.4 -2.9%
Unituxin 48.6 53 -8.3%
Comprehensive Income 263.8 324.4 -18.7%
Other Comprehensive Income -11.1 2.2 -604.5%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -11.1 2.2 -604.5%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 1,279.7 1,899.9 -32.6%
Marketable Securities (Current) 874 1,421.4 -38.5%
Accounts Receivable 312 322 -3.1%
Inventory 178.3 165.4 +7.8%
Other Assets Current 228 131.1 +73.9%
Total Current Assets 2,872 3,939.8 -27.1%
Non-Current Assets
Marketable Securities (Non-Current) 1,317.4 1,710.7 -23.0%
Property, Plant & Equipment 1,840.7 1,302.7 +41.3%
Deferred Tax Assets 335.4 456.6 -26.5%
Other Non-Current Assets 233.2 222.4 +4.9%
Total Assets 6,714.2 7,743.9 -13.3%
Other Assets
Intangible Assets Net Including Goodwill 115.5 111.7 +3.4%
Current Liabilities
Accounts Payable And Accrued Liabilities Current 498.3 367 +35.8%
Other Liabilities Current 100.8 154.5 -34.8%
Total Current Liabilities 599.1 721.5 -17.0%
Non-Current Liabilities
Other Non-Current Liabilities 214 215.2 -0.6%
Total Liabilities 813.1 936.7 -13.2%
Stockholders' Equity
Common Stock 0.8 0.8 0.0%
Additional Paid In Capital Common Stock 2,520.3 2,737.7 -7.9%
Accumulated Other Comprehensive Income -10.2 -1.2 -750.0%
Treasury Stock Common Value -5,441.6 -3,474.5 -56.6%
Retained Earnings 8,831.8 7,544.4 +17.1%
Total Stockholders' Equity 5,901.1 6,807.2 -13.3%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -10.2 -1.2 -750.0%
Additional Paid In Capital 2,520.3 2,737.7 -7.9%
Common Stock 0.8 0.8 0.0%
Retained Earnings 8,831.8 7,544.4 +17.1%
Treasury Stock Common -5,441.6 -3,474.5 -56.6%
Total Liabilities & Equity 6,714.2 7,743.9 -13.3%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation & Amortization 22.6 19.8 +14.1%
Stock-Based Compensation 33.9 31.8 +6.6%
Equity Securities Fv Ni Unrealized Gain Loss 61.6 5.3 +1062.3%
Show Income Statement Location breakouts
Other Nonoperating Income Expense 61.6 5.3 +1062.3%
Deferred Income Taxes 25.9 — —
Other Non-Cash Items 32 4.1 +680.5%
Change in Accounts Receivable 38.2 -42.7 +189.5%
Change in Inventory -40.1 -11.2 -258.0%
Increase Decrease In Accounts Payable And Accrued Liabilities -12.7 -2.6 -388.5%
Increase Decrease In Other Operating Capital Net 27 134.5 -79.9%
Net Cash from Operations 463.3 461.2 +0.5%
Investing Activities
Capital Expenditures -100.8 -74.9 -34.6%
Advance Payment Related To Property Plant And Equipment -5.7 -9.2 +38.0%
Purchases of Investments -701.7 -692.3 -1.4%
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 269 611.7 -56.0%
Proceeds From Sale Of Available For Sale Securities Debt 1,307.9 — —
Payments To Acquire Equity Securities Without Readily Determinable Fair Value -25 — —
Net Cash from Investing 743.7 -164.7 +551.5%
Financing Activities
Share Repurchases -1,500 — —
Proceeds From Stock Options Exercised 68.3 16.6 +311.4%
Show Award Type breakouts
Employee Stock Option 68.3 16.6 +311.4%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans 5.6 4.9 +14.3%
Tax Withholding for Share Compensation -58.3 -15.3 -281.0%
Net Cash from Financing -1,484.4 -93.8 -1482.5%
Supplemental
Interest Paid 1.9 5.4 -64.8%
Income Taxes Paid 1.5 0.5 +200.0%
Unpaid Capital Expenditures 99.6 47.2 +111.0%
Noncash Excise Tax On Net Share Repurchases 8.4 — —
Other Cash Flow
Net Change in Cash -277.4 202.7 -236.9%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,279.7 1,899.9 -32.6%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key